Company Overview and News

 
Organovo to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Tyrosinemia I at the Liver Meeting® 2018 (AASLD)

2018-10-15 globenewswire
SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced it will present data on the performance of its liver therapeutic tissue in an animal model of hereditary tyrosinemia Type 1 (“HT-1”) at the Liver Meeting 2018® (American Association for the Study of Liver Diseases or “AASLD”) being held November 9-13, 2018 in San Francisco.
ONVO

 
Organovo to Present at 2018 Cell & Gene Meeting on the Mesa

2018-09-26 globenewswire
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that Chief Executive Officer, Taylor J. Crouch, is scheduled to speak at the Cell & Gene Meeting on the Mesa to be held October 3-5 in La Jolla, Ca.
ONVO

 
ONVO / Organovo Holdings, Inc. 8-K (Current Report)

2018-08-15 sec.gov
onvo-8k_20180815.htm UNITED STATES SECURITIES AND
ONVO

 
ONVO / Organovo Holdings, Inc. S-8

2018-08-14 sec.gov
S-8 As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. 333-
ONVO

 
ONVO / Organovo Holdings, Inc. S-8

2018-08-14 sec.gov
S-8 As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. 333-
ONVO

1
Organovo Holdings, Inc. (ONVO) CEO Taylor Crouch on Q1 2019 Results - Earnings Call Transcript

2018-08-09 seekingalpha - 1
Organovo Holdings, Inc. (NASDAQ:ONVO) Q1 2019 Results Earnings Conference Call August 9, 2018 5:00 PM ET
ONVO IONS

 
ONVO / Organovo Holdings, Inc. 8-K (Current Report)

2018-08-09 sec.gov
onvo-8k_20180809.htm UNITED STATES SECURITIES AND
ONVO

 
ONVO / Organovo Holdings, Inc. 10-Q (Quarterly Report)

2018-08-09 sec.gov
onvo-10q_20180630.htm UNITED STATES
ONVO

 
Organovo Announces Appointment of Steven G. Hughes, M.D. as Chief Medical Officer

2018-08-01 globenewswire
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that Steven G. Hughes has been named Chief Medical Officer. Dr. Hughes is an industry veteran who brings significant experience directing clinical development and medical affairs teams at leading biopharma companies.
ONVO IONS

5
Organovo Needs A Business Transplant

2018-07-30 seekingalpha - 4
ONVO essentially admitted on their recent earnings call that their existing business will never be profitable and is purely a “funding mechanism” for advancing their therapeutic tissue (NovoTissue) program.
PFZ ONVO UTHR 500680 PFE PFIZER

 
ONVO / Organovo Holdings, Inc. 8-K (ANNUAL MEETING RESULTS) (Current Report)

2018-07-27 sec.gov
onvo-8k_20180726.DOCX.htm UNITED STATES SECURITIES
ONVO

 
Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Results

2018-07-19 globenewswire
SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, August 9, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal first-quarter 2019 operating and financial highlights. In advance of the call on August 9, 2018, Organovo will issue its fiscal first-quarter 2019 earnings press release, which will be available at http://www.
ONVO

 
Organovo Shareholders Could Have Even More Downside Ahead

2018-07-03 seekingalpha
Organovo Holdings (ONVO) is potentially 2-3 years away from a multi-billion-dollar revenue stream from their treatments for liver diseases.
DDD SSYS ONVO

52
ONVO / Organovo Holdings, Inc. DEF 14A

2018-06-15 sec.gov - 6
onvo-def14a_20180726.htm UNITED STATES
ONVO

58
ONVO / Organovo Holdings, Inc. DEFA14A

2018-06-15 sec.gov - 12
onvo-defa14a_20180726.htm
ONVO

ONVO : Organovo Holdings Stock Analysis and Research Report

2017-10-30 - Asif

Organovo Holdings, Inc. is an early commercial stage company focused on developing and commercializing functional three-dimensional (“3D”) human tissues. Using its proprietary technologies and expertise in bioprinting, Organovo Holdings is building functional 3D human tissues that mimic key aspects of native biology, and can be used in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. Organovo Holdings is utilizing its proprietary bioprinting platform to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Organovo Holdings is leveraging its unique tissue models to improve the current industry standard cell-based and animal model testing approaches, and the company believe its foundational approach provides it with the opportunity to fill many critical gaps in commercially available preclinical human tissue models as well as in tissue trans...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ONVO / Organovo Holdings, Inc. on message board site Silicon Investor.

Organovo (ONVO) Organovo (ONVO) Organovo (ONVO)
CUSIP: 68620A104